Skip to main content
. 2020 Dec 14;11:606923. doi: 10.3389/fneur.2020.606923

Figure 1.

Figure 1

The median and interquartile range of mRS. The median mRS significantly decreased from 3.5 (interquartile range, 3–4) before rituximab treatment to 0.5 (interquartile range, 0–1) at the last follow-up (before patient 3 and patient 6 had severe infectious adverse events) (P = 0.0201).